N-glycan as new potential biomarker for predicting treatment response in patients with type 2 diabetes mellitus.

Autor:	Dong HJ; Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China., Li XH; Department of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Gu QX; Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China., Ma CF; Department of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Yuan MX; Department of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Wang ZZ; Department of laboratory medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Su JR; Department of laboratory medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Xu L; Department of Research and Development, Sysdiagno (Nanjing) Biotech Co., Ltd, Nanjing, Jiangsu Province, China., Chen CY; Department of Research and Development, Sysdiagno (Nanjing) Biotech Co., Ltd, Nanjing, Jiangsu Province, China., Ebule Q; Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China., Zhuang H; Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China., Liu XE; Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Jazyk:	angličtina
Zdroj:	Biomarkers in medicine [Biomark Med] 2024 Dec; Vol. 18 (24), pp. 1113-1122. Date of Electronic Publication: 2024 Nov 25.
DOI:	10.1080/17520363.2024.2432309
Abstrakt:	Aims: To investigate the N-glycans related to the metformin efficacy in patients with type 2 diabetes mellitus (T2DM). Materials and Methods: We enrolled 141 healthy controls and 195 newly diagnosed T2DM patients treated with metformin for 3 months. Serum N-glycan profile was determined by DNA sequencer - assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). The N-glycan model was established by logistic regression analysis. Receiver operating characteristic curve (ROC) analysis was used to analyze the predictive power of the N-glycan model for metformin efficacy. Results: The abundances of several N-glycans in serum of T2DM patients at baseline were significantly different from those of healthy controls and tended to recover the N-glycan of controls after 3 months treatment. Serum N-glycans changes were more significant in the good response group (FPG <7 mmol/L) after metformin treatment. In addition, the abundance of peak9 at baseline had an opposite tendency between HbA1c increased and decreased groups post-treatment, which could be a biomarker for predicting metformin efficacy. Peak9 combined with other 11 N-glycans at baseline was used to establish the predictive model to distinguish non-response from response patients (AUROC = 0.780, sensitivity = 70.6% and specificity = 77.5%). Conclusions: Serum N-glycans may have potential value as biomarkers for indicating the efficacy of metformin.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu